TY - JOUR T1 - ▼Rivastigmine for Alzheimer's disease JF - Drug and Therapeutics Bulletin JO - Drug Ther Bull SP - 15 LP - 16 DO - 10.1136/dtb.2000.38215 VL - 38 IS - 2 A2 - , Y1 - 2000/02/01 UR - http://dtb.bmj.com/content/38/2/15.abstract N2 - Relevant BNF section: 4.11▼Rivastigmine (Exelon - Novartis) is the second cholinesterase inhibitor marketed for symptomatic treatment of mild to moderately severe Alzheimer's dementia, and follows ▼donepezil (Aricept - Eisai; Pfizer). Previously, we have been "unconvinced of the value of donepezil in routine clinical practice".1,2 Rivastigmine has been promoted with the slogan "Beyond cognition: improving functional ability". Does rivastigmine offer useful benefits in Alzheimer's disease? ER -